Janssen vs Otsuka expects domestic competition for long-acting schizophrenia drugss
In the schizophrenia treatment market, competition to introduce long-acting injections has become active.
Leading pharmaceutical companies in the field, Janssen and Otsuka, have released follow-up products in series.
Janssen is currently going through the approval procedure of the upgraded vers...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
